Evidence map›Paper›PMID 35272487›Full record

ArticleBone & joint research2022

The role of accelerated growth plate fusion in the absence of SOCS2 on osteoarthritis vulnerability.

Hasmik Jasmine Samvelyan, Carmen Huesa, Lin Cui, Colin Farquharson, Katherine Ann Staines

Open access · goldAbstract read
In one paragraph

Article in Bone & joint research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Hasmik Jasmine SamvelyanSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK.
Carmen HuesaInstitute of Infection, Immunity & Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Lin CuiThe Roslin Institute, The University of Edinburgh, Edinburgh, UK.
Colin FarquharsonThe Roslin Institute, The University of Edinburgh, Edinburgh, UK.
Katherine Ann StainesSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK.ORCID 0000-0002-8492-9778
Roslin Institute · GBAnglia Ruskin University · GBUniversity of Brighton · GBUniversity of Glasgow · GB

Funding

Medical Research Council MR/R022240/2Versus Arthritis 22483
6 · The paper itself

Abstract

aimsOsteoarthritis (OA) is the most prevalent systemic musculoskeletal disorder, characterized by articular cartilage degeneration and subchondral bone (SCB) sclerosis. Here, we sought to examine the contribution of accelerated growth to OA development using a murine model of excessive longitudinal growth. Suppressor of cytokine signalling 2 (SOCS2) is a negative regulator of growth hormone (GH) signalling, thus mice deficient in SOCS2 (

methodsWe examined vulnerability of

resultsWe observed a significant increase in mean number (wild-type (WT) DMM: 532 (SD 56); WT sham: 495 (SD 45); knockout (KO) DMM: 169 (SD 49); KO sham: 187 (SD 56); p < 0.001) and density (WT DMM: 2.2 (SD 0.9); WT sham: 1.2 (SD 0.5); KO DMM: 13.0 (SD 0.5); KO sham: 14.4 (SD 0.7)) of growth plate bridges in

conclusionTogether, these data suggest that enhanced GH signalling through SOCS2 deletion accelerates growth plate fusion, however this has no effect on OA vulnerability in this model. Cite this article:

Indexed as

articular cartilage damagearticular cartilage lesionsBonebone growthCartilagecytokinedestabilization of the medial meniscus (DMM)Growth hormoneGrowth plategrowth platesmicro-CT scansmurine modelOsteoarthritisOsteoarthritis (OA)SOCS2Subchondral bone

Identifiers

PMID35272487
PMCPMC8962856
OpenAlexW4221123753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.